Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 23, 2026.

Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease

Xian-Si Zeng, Wen-Shuo Geng, Jin-Jing Jia and 2 more

Frontiers in Aging Neuroscience · 2018 · Review

doi:10.3389/fnagi.2018.00109

Abstract

It has been 200 years since Parkinson disease (PD) was described by Dr. Parkinson in 1817. The disease is the second most common neurodegenerative disease characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Although the pathogenesis of PD is still unknown, the research findings from scientists are conducive to understand the pathological mechanisms. It is well accepted that both genetic and environmental factors contribute to the onset of PD. In this review, we summarize the mutations of main seven genes (α-synuclein, LRRK2, PINK1, Parkin, DJ-1, VPS35 and GBA1) linked to PD, discuss the potential mechanisms for the loss of dopaminergic neurons (dopamine metabolism, mitochondrial dysfunction, endoplasmic reticulum stress, impaired autophagy, and deregulation of immunity) in PD, and expect the development direction for treatment of PD.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Parkinson disease (PD) is the second most common neurodegenerative disease after Alzheimer disease. In 1817, an English physician, Dr. James Parkinson, firstly described the pathological characteristic of paralysis agitans (shaking palsy), and the pattern was eventually called “PD” by Charcot and Vulpian in 1862. In 1912, Friederich Lewy first described the intraneuronal inclusions, namely “Lewy bodies” which define shaking palsy at a neuropathological level, and provided a detailed histopathological analysis of the nervous system to further understanding of shaking palsy. Now PD is known as a progressive, neurodegenerative disorder characterized by severe motor symptoms, including static tremor, postural imbalance, bradykinesia and muscle rigidity. α-synuclein is the main component of Lewy bodies and has a central role in PD. Epidemiological investigations have disclosed that few of PD patients are hereditable forms, while the overwhelming majority are sporadic forms. The prevalence of PD varies with age, from 1–2% at ages of 55–65 years to 3.5% at 85–89 years. Unfortunately, the ultimate cause of PD is not well understood yet.

Although the pathological mechanisms are largely unknown, both genetic and environmental factors are considered to involve in potential pathogenesis of PD. Polymeropoulos et al identified the first PD-linked mutation, α-synuclein (A53T), in Italian and Greek origin families in. found that four persons with notable parkinsonism after intravenous injection of an illicit drug, containing 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in 1983. Afterward, many PD-linked gene mutations and several environmental factors were found. The potential mechanisms for loss of dopaminergic neurons were also well studied. In this review, we summarize the mutations of main seven genes (α-synuclein, LRRK2, PINK1, Parkin, DJ-1, VPS35 and GBA1) associated to PD and potential mechanisms for loss of dopaminergic neurons (dopamine metabolism, mitochondrial dysfunction, endoplasmic reticulum stress, impaired autophagy, and deregulation of immunity), and also expect the development direction for treatment of PD.

Genetic Basis of PD

There is an increasing list of mutations related to the onset of PD. They account for more than 50% of early-onset cases and about 2–3% of late-onset forms of PD. Findings of gene mutations linked to the onset of familial PD cases have confirmed their critical roles in the progress of PD and made it easy to understand the molecular pathogenesis for hereditary PD.

α-synuclein

A missense mutation in α-synuclein (A53T), encoded by the SNCA/PARK1 gene, was firstly identified to cause a familial form of PD. Soon afterward, series of missense point mutations in the N-terminal of α-synuclein, including A30P, E46K, H50Q, G51D and A53E, were also identified. SNCA-linked PD is often of early onset and usually progresses rapidly. α-synuclein is the main component in Lewy bodies and most is phosphorylated at Ser129 of α-synuclein, which facilitated α-synuclein fibril uptake by neurons and exacerbated the pathology progression of PD. Rodriguez et al have revealed the structure of toxic core of α-synuclein as pairs of face-to-face b-sheets by using micro-electron diffraction. The α-synuclein variants forming oligomers were more toxic than that forming fibrils, so the former triggered more severe loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) in animals. The dosage of α-synuclein gene(SNCA) is responsible for parkinsonism. Point mutation and triplication carriers show almost complete penetrance, whereas penetrance in duplication carriers ranges between 30% and 50%. What’s more, SNCA triplication carriers also tend to have even earlier onset and more severe phenotype than duplication carriers. Triplication of SNCA gene triggered unfolded protein response in induced pluripotent stem cells (iPSCs) generated from a patient with PD.

Mutations of α-synuclein are toxic to dopaminergic neurons because they alter a series of intracellular signal programs. α-synuclein A53T mutation could suppress autophagy in the brain of transgenic mice at early stage and lead to synucleinopathy. A53T also induces mitochondrial dysfunction- and endoplasmic reticulum stress-mediated cell death pathways in PC12 cells. Proteasomal protein cleavage is significantly impaired by overexpression of mutant α-synuclein in dopaminergic cells, such as SH-SY5Y and PC12. have reported that erythrocyte-derived extracellular vesicles containing α-synuclein could transmit across the blood brain barrier; this may be a new mechanism by which the brain and periphery communicate throughout the initiation and development of PD. α-synuclein specifically binds to TrkB receptors and inhibits BDNF/TrkB signaling pathway, resulting in the death of dopaminergic neurons. Another mutation A30P could promote the neurodegeneration of dopaminergic neurons via activating microglia and upregulating the expression of PHOX and Mac-1. The mutations of α-synuclein linked to PD and the pathogenesis are summarized in Table 1.

Both mRNA and protein levels of α-synuclein showed a double increase in PD, therefore, reducing α-synuclein expression may provide a potential therapeutic approach. have clarified that knockdown of α-synuclein by using a shRNA attenuates the progressive motor deficits and the degeneration of dopaminergic neurons in SNc in rotenone-induced rats model of PD. Intranasal delivery of inhibitory oligonucleotides, siRNA or antisense oligonucleotide combined with the triple monoamine reuptake inhibitor indatraline selectively decreases α-synuclein expression in the brainstem of mice and reduces levels of endogenous α-synuclein mRNA and protein in SNc. Systemic exosomal siRNA delivery also significantly reduced the aggregation of α-synuclein in SNc dopaminergic neurones of S129D α-synuclein transgenic mice.

LRRK2

Leucine-rich repeat kinase 2(LRRK2) is a multi-domain protein, containing both Rab GTPase and kinase enzymatic activities. LRRK2 mutations are linked with “classical” late-onset PD and accounts for 4% of hereditary PD. The penetrance is incomplete and age-dependent. Mutations of LRRK2/PARK8 gene represent the highest risk of familial PD, causing autosomal dominant PD. Morbidity of PD is significantly elevating among LRRK2 G2019S mutation carriers as aging. LRRK2 G2019S mutation elevates mobility of α-synuclein and enhances α-synuclein accumulation in cultured primary neurons and in dopaminergic neurons in SNc of PD brain. The mutation also promotes the transmission of Tau in the mouse brain neurons, implicating for understanding the development of tau protein neuropathology in LRRK2-linked PD. Pathogenic mutations in LRRK2 increase its kinase activities in cells and tissues, so small molecule inhibitors of LRRK2 kinase can be used to block its activity to provide neuroprotection in some PD models. Intracerebral injection of LRRK2 antisense oligonucleotides also decreases endogenous protein levels of normal LRRK2 and inhibits the formation of fibril-induced α-synuclein inclusions.

LRRK2 not only inhibits neuronal survival but also impairs dopamine signal. LRRK2 played important roles in the death of neurons via directly phosphorylating apoptosis signal-regulating kinase 1 at Thr832 site and activating the kinase activity. In model organisms, it has numerous roles within the secretory pathway and may contribute to dopaminergic signaling. LRRK2 could promote neuronal death via inhibiting myocyte-specific enhancer factor 2D activity, which is required for neuronal survival. LRRK2 G2019S mutation impairs dopamine receptor D1 internalization, leading to an alteration in signal transduction. In addition, LRRK2 G2019S mutation enhances the kinase activity and results in the impairment of synaptic vesicle trafficking selectively in ventral midbrain neurons, including dopaminergic neurons.

LRRK2 G2019S mutation shows a close relationship with mitochondrial dysfunction. have reported that this mutation induces mitochondrial DNA damage in cultured primary neurons from rat midbrain, which is dependent on LRRK2 kinase activity, and pharmacological inhibition restores the integrity of mitochondrial DNA. PD-associated LRRK2 mutations upregulate the expression of mitochondrial calcium uniporter, a mitochondrial calcium transporter and then promote the uptake of dendritic and mitochondrial calcium in cortical neurons and familial PD patient fibroblasts. LRRK2 G2019S binds to and enhances its interaction with mitochondrial dynamin-like protein 1(DLP1, a fission protein), which increases mitochondrial DLP1 levels and induces neuronal toxicity, mitochondrial fragmentation, and mitochondrial dysfunction. LRRK2 G2019S mutation also impairs mitochondrial function by decreasing the activity of respiratory chain complex IV, whereas siRNA-mediated knockdown of LRRK2 restores the mitochondrial morphology. Ursocholanic acid and ursodeoxycholic acid improves the LRRK2 G2019-decreased mitochondrial function in vitro and in vivo, suggesting that ursocholanic acid and ursodeoxycholic acid may be promising drugs for future neuroprotective trials. The mutations of LRRK2 linked to PD and the pathogenesis are summarized in Table 2.

PINK1 and Parkin

PTEN-induced putative kinase (PINK) 1, a mitochondrial protein kinase, is a critical protein linked with the pathogenesis of PD. PINK1 deficiency causes the autosomal recessive PARK6 variant of PD. PINK1 mutations have been reported to account for approximately 1–3% of early onset PD in populations of European ancestry, 8.9% of autosomal recessive PD in a sample of Japanese families, and 2.5% of early onset PD in a sample of ethnic Chinese, Malays, and Indians. PINK1 loss is associated with mitochondrial dysfunction and mitochondrial Ca2+ mishandling via directly interacting with and phosphorylating LETM1 at Thr192 site to increase Ca2+ release and facilitate its transport. In a Caenorhabditis elegans Model of PD, non-apoptotic neurodegeneration of dopaminergic cells is induced by the dysregulation of mitochondrial unfolded protein response, which is dependent on the PINK1 homolog. Heterozygous PINK1 G411S mutation shows a significant decrease in kinase activity of PINK1 and could increase the risk of PD via a dominant-negative mechanism. Mutation of PINK1 show an accumulation of dysfunctional mitochondria with age, leading to activation of the mitochondrial unfolded protein response, which promotes longevity and dopamine neuron survival in PD models. I368N and Q456X mutations of PINK1 reduce either its stability/protein levels or kinase activity, increasing the risk of PD. Other mutations, including A168P, H271Q, L347P and G309D, weaken the recruitment of Parkin to depolarized mitochondria.

Parkin, encoded by PARK2, is originally considered to serve as a ubiquitin E3 ligase, which can be activated by autophosphorylated PINK1 and is required for the ubiquitin-proteasome degradation of target substrates. Mutations in the Parkin gene are a common cause of early onset PD in many countries and account for 10–25% of cases. PINK1 accumulates on the membrane of dysfunctional mitochondria, activates the E3 ubiquitin ligase activity of Parkin and recruits them to damaged mitochondria from cytoplasm to promote their mitophagic degradation. Reactive oxygen species also induces PINK1/Parkin pathway-dependent mitophagy by promoting Parkin recruitment to mitochondria. Mutations of Parkin, including R42P, R46P, K211N, C212Y, C253Y, C289G, and C441R, cause a deficit in its recruitment to depolarized mitochondria and further inhibit mitophagy. Silence of PINK1/Parkin by siRNA promotes mitochondrial fragmentation in cultured primary neurons of mouse. The mutations of PINK1 and Parkin linked to PD and the pathogenesis is summarized in Table 3.

DJ-1

Mutations of DJ-1, encoded by the PARK7 gene, have been linked with early onset of recessive PD, which were first identified in 2 European families with an age of onset of 20–40 years. Several PD-associated DJ-1 mutations have been identified, including L166P, M26I, L10P and P158Δ. Recently, genetic analysis from a single case research reveals a novel mutation of L172Q in the PARK7 gene, which is the first time to report the neuropathology from a DJ-1-linked PD brain. DJ-1 could interact with and steady PINK1 in cells overexpressing PINK1. DJ-1 has been reported to also interact with α-synuclein, modulate its aggregation by weak hydrophobic interaction and restore α-synuclein-induced cellular toxicity.

The neuroprotective roles mediated by DJ-1 are summarized as anti-oxidant properties, anti-apoptotic effects, effects on mitochondrial respiratory function, morphology, turnover and biogenesis. Currently, the most acknowledged role of DJ-1 in the pathophysiology of PD is the neuroprotective function against oxidative stress. DJ-1 mutations mainly affect a protein involved in intracellular oxidation-reduction. Mutant DJ-1(L166P and M26I) increases the sensitivity of SHSY5Y cells toward oxidative stress, because it abolishes the neuroprotection against H2O2 and the induction of thioredoxin-1 through inhibiting nuclear factor erythroid-2 related factor 2 signal pathway. D149A mutation also abolishes its protection. The three mutations, L172Q, L10P and P158Δ, are involved in reduction of protein stability. DJ-1 deficiency in neurons shows a decrease of glutamine influx and serine biosynthesis, which attenuates cellular antioxidant response and leads to the degeneration of dopaminergic neurons. DJ-1-Deficiecy in embryonic stem cells-derived dopaminergic neurons also increases the sensitivity to toxins-induced oxidative stress. Drosophila carrying a mutant DJ-1β gene, the homologue of human DJ-1, show a reduced climbing ability reflecting locomotor defects. DJ-1 overexpression ameliorates mitochondrial function, including the mitochondrial quantity and activity of respiratory chain complex I, by phosphorylating Akt at Thr308 site in both SH-SY5Y and PC-12 cells. Recombinant DJ-1 can also reverse dopamine depletion in α-synuclein or 6-hydroxydopamine (6-OHDA)-triggered dopaminergic degeneration in vivo. Some natural compounds protect against neurotoxin-induced Parkinsonism by upregulating DJ-1 expression. A marine compound exerts neuroprotective effects through upregulating DJ-1 expression and activating DJ-1-targeted pathway in 6-OHDA-induced zebrafish and rat models of PD. A standardized flavonoid extract from Safflower restores the expression of DJ-1, as well as the expression of tyrosine hydroxylase and dopamine transporter in rotenone-induced Parkinson rats. The mutations of DJ-1 linked to PD and the pathogenesis is summarized in Table 4.

VPS35

Mutations of the Vacuolar protein sorting 35 (VPS35) gene were first discovered in an Austrian family with late-onset PD. It accounts for 1% of familial PD. VPS35, a major component of the retromer cargo-recognition complex, regulates the process of transmembrane protein sorting between endosomes and the Golgi. It has been reported that VPS35 D620N mutation is pathogenic in patients with PD in Asian, European and American families. VPS35 D620N mutation led to a decrease of enzymatic activity in complex I and II in PD patient fibroblasts and caused mitochondrial dysfunction by recycling DLP1 complexes. What’s more, VPS35 deficiency also led to mitochondrial dysfunction and finally resulted in the loss of dopaminergic neurons. VPS35 mutant D620N disrupted the interaction of VPS35 with aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 (AIMP2), a Parkin substrate, and lysosome-associated membrane protein-2a (LAMP2A). Overexpression of VPS35 inhibited AIMP2-enhanced cell death in SH-SY5Y cells; In contrast, downregulation of VPS35 resulted in AIMP2 dependent-cell death. VPS35-deficient DA neurons exhibit impaired endosome-to-Golgi retrieval of Lamp2a, which may contribute to the reduced α-synuclein degradation through chaperone-mediated autophagy. Co-expression of high copy numbers of VPS35 D686N (the yeast equivalent of D620N) and low copy numbers of α-synuclein caused toxicity. Another PD-linked VPS35 mutation R524W impaired the endosomal association of retromer and also induced the aggregation of α-synuclein. In a Drosophila model, VPS35 P316S mutation also produced some of PD phenotypes, including reduction of climbing ability and loss of dopaminergic neurons, enhanced the susceptibility of Drosophila to rotenone. The mutations of VPS35 linked to PD and the pathogenesis is summarized in Table 5.

GBA1

Glucocerebrosidase (GBA1) gene mutations, encoding gluco-cerebrosidase 1 (GCase 1) which catabolizes glycolipid glucocerebroside to ceramide and glucose in lysosome and responsible for Gaucher disease, are the most common genetic risk factor for PD. It is recently reported that both heterozygous and homozygous mutations of the GBA1 gene have been linked to PD, with more than 10% of individuals carrying GBA1 mutations developing PD by the age of 80. A significant and progressive reduction in GCase 1 activity and protein levels is also observed in the brains and cerebrospinal fluid of PD patients. Activation of GCase 1 by using a small-molecule modulator restored the function of lysosome and then cleared the accumulation of pathological α-synuclein in midbrain neurons of PD patients, indicating the potential importance of GCase 1 in the development of idiopathic PD. It is estimated that about 10–25% of PD cases carry a GBA1 mutation, in which N370S and L444P are the most common mutations. GBA1 knockout inhibited macroautophagy and chaperone-mediated autophagy in MEFs and downregulation of GCase 1 increased α-synuclein protein levels in SH-SY5Y cells. GBA1 deficiency also resulted in the accumulation of glycosphingolipids (GSL), then decreased α-synuclein tetramers resisting aggregation and related multimers and increased α-synuclein monomers in CRISPR-GBA1 knockout SH-SY5Y cells. What’s more, α-synuclein tetramers and related multimers were also reduced in PD induced pluripotent stem cell (iPSC)-derived human dopaminergic neurons carrying N370S GBA1 mutation. In contrast, inhibition of GSL accumulation and overexpression of GBA1 to enhance GCase 1 activity reverse the destabilization of α-synuclein tetramers and protect against α-synuclein preformed fibril-induced toxicity in human dopaminergic neurons. N370S mutation produced GCase 1 retention within the endoplasmic reticulum, interrupting its traffic to the lysosome, leading to endoplasmic reticulum stress activation and triggering unfolded protein response and Golgi apparatus fragmentation. Decreased α-synuclein tetramers and related multimers were also observed in murine neurons carrying the heterozygous L444P GBA1 mutation and L444P GBA1 mutation aggravated α-synuclein-induced loss of dopaminergic neurons in SNc of 24-month-old mice. The mutations of GBA1 linked to PD and the pathogenesis is summarized in Table 6.

Mechanisms of Neuronal Cell Death in PD

The most obvious progress has been made in understanding the proximate causes, especially the deaths of dopaminergic neurons that explain the classic motor symptoms of the disease. The deaths mainly occur in the SNc, in which the neurotransmitter dopamine is normally synthesized and pumped into movement-regulating brain regions. Though up to 70% of these dopaminergic neurons in SNc will be killed during the development of PD, symptoms are seldom noticed because the striatum, immediately downstream of the SNc, can compensate to some extent. However, massive neurons in the striatum also start to die eventually. Currently, it is widely accepted that dopamine metabolism, oxidative stress and mitochondrial dysfunction, endoplasmic reticulum stress, impairment of protein degradation systems, and neuroinflammation are involved in the death of dopaminergic neurons in SNc (Table 7).

Dopamine Metabolism

Parkinson disease is a movement disorder and the first neurodegenerative disease, which is confirmed severe depletion of dopamine (regulates Parkinson’s tremor) in the striatum. Oxidation of dopamine could induce oxidative stress and is harmful to dopaminergic neurons. Mitochondrial oxidative stress results in the accumulation of oxidized dopamine and ultimately leads to reduced activity of glucocerebrosidase, lysosomal dysfunction, and α-synuclein accumulation in human and PD neurons. Increased levels of dopamine in cytoplasm and its metabolites are neurotoxic and lead to selective death of neurons in SNc, administration that decreases cytoplasmic dopamine levels provide neuroprotection in cultured midbrain neurons. Aminochrome, which is formed within the cytoplasm during the auto-oxidation of dopamine to neuromelanin, could induce neurotoxicity in dopaminergic neurons when DT-diaphorase and glutathione transferase mutate. Auto-oxidation of dopamine aggravates overexpression of human α-synuclein A53T mutation-induced non-apoptotic cell death in PC12 cells. Dopamine not only spontaneously oxidize to form melanin and neuromelanin, but also is catalyzed to the immediate products being hydrogen peroxide and aldehydes by monoamine oxidase. Monoamine oxidase in the outer membrane of mitochondria catalyzes conversion of cytosolic dopamine to 3,4-dihydroxyphenylacetaldehyde, which is an endogenous neurotoxin implicated in PD, cause extensive aggregation of glyceraldehyde-3-phosphate dehydrogenase and irreversibly inhibit the enzyme activity, resulting in the production of reactive oxygen species to damage neurons. Dopamine also induces the production of soluble A53T α-synuclein oligomers and promotes the degeneration of neurons in SNc. Vesicular uptake inhibition of dopamine with Reserpine rapidly increases the cytosolic concentration of 3,4-dihydroxyphenylacetaldehyde, contributing to the dimerization of α-synuclein and apoptosis. Dopamine induces mitochondrial permeability transition pore opening via production of reactive oxygen species in mouse neurons with PINK1 defect. Reuptake of extracellular dopamine to cytoplasm leads to accumulation of dopamine, which triggers neurotoxicity in dopaminergic neurons. Disrupting the interaction between dopamine D2 receptor and dopamine transporter provides a protective role against dopamine neurotoxicity.

Mitochondrial Dysfunction

Mitochondrial disorders have been implicated in almost all neurodegenerative diseases, including PD. PD-linked mutations could induce mitochondrial dysfunction. Soluble prefibrillar α-synuclein oligomers showed several phenotypes of mitochondrial dysfunction observed previously in cell and animal models of PD: dysfunction of complex I, change in membrane potential, disruption of Ca2+ homeostasis, and enhanced release of cytochrome c. PD-associated mutation of VPS35 gene, encoding a key component of the retromer complex, leaded to mitochondrial fragmentation and neuronal death in vitro and in vivo by enhanced interactions with DLP1. Inhibiting the enzymatic activity of the GCase 1, or silencing the GBA1 gene in SH-SY5Y, also caused mitochondrial dysfunction, showing reduced activity of mitochondrial respiratory chain and mitochondrial depolarization and fragmentation associated with increased levels of ROS. In the SNc of idiopathic PD patients, the expression of mitochondrial DNA transcription factors (TFAM and TFB2M) is decreased. Consistent with this, real-time PCR analysis exhibits a reduced copy number of mitochondrial DNA and fewer molecules associated with transcription/replication in PD patients. 4-hydroxynonenal, a lipid peroxidation product, promotes the intracellular accumulation, extrusion of extracellular vesicles containing toxic α-synuclein, and then internalization into neighboring neurons, finally results in the neurodegenerative development of PD.

Numerous studies have repeatedly demonstrated that the expression and activity of respiratory chain complex I are markedly reduced in PD. The initial evidence is that exposure to environmental 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) caused degeneration of dopaminergic neurons and parkinsonism. MPTP, a PD neurotoxin, is metabolized to its active metabolite MPP+ by monoamine oxidase and then is transferred into dopaminergic neurons by dopamine transporter. MPP+ is considered as an inhibitor of mitochondrial complex I, inhibits ATP production, then results in the generation of superoxide and peroxynitrite, and finally ablates dopaminergic neurons. Partial deficiency of mitochondrial complex I in dopaminergic neurons increases the vulnerability of mice toward MPTP. Other neurotoxins can also induce degeneration of dopaminergic neurons and parkinsonism. The herbicide paraquat, reduced by NADPH oxidase on microglia, is also transported into dopaminergic neurons by dopamine transporter, where it induces mitochondrial dysfunction and neurotoxicity. Injection of PD neurotoxin 6-OHDA into the right SNc also reduces activity of mitochondrial oxidative phosphorylation enzymes, particularly selective decrease of complex I activity. Chronic treatment of rodents with pesticide rotenone, a well-established complex I inhibitor, selectively induces toxicity to dopaminergic neurons.

There is a potential interaction between environmental neurotoxin-induced mitochondrial dysfunction and genetic risk factors in PD pathogenesis. Injection of sub-toxic MPTP enhances the neurotoxicity of mutant α-synuclein and induces vulnerability of dopamine neurons, which may be due to the downregulation of DJ-1. The higher level of neurotoxicity in SNc than VTA neurons is due to SNc neuron-specific MPP+-induced increase in cytosolic dopamine and Ca2+, followed by an elevation of mitochondrial Ca2+ and mitochondrial oxidation, which is dependent on the expression of α-synuclein. A long non-coding RNA promotes MPTP-induced parkinsonism via upregulating the expression of LRRK2. Mice expressing LRRK2 G2019S mutation exhibit elevated susceptibility to MPTP-induced neurotoxicity. Downregulation of PINK1 enhances the sensitivity of dopaminergic neurons to MPTP-induced neurotoxicity, which can be inhibited by overexpression of Parkin or DJ-1.

Endoplasmic Reticulum Stress

Parkinson disease is a disease classified as protein-misfolding disorders. Endoplasmic reticulum stress is observed in the SNc of PD patient brain and results in the death of dopaminergic neurons. Increasing experimental evidence have also indicated that the accumulation of misfolded or unfolded proteins results in endoplasmic reticulum stress, which contributes to the neuronal death or apoptosis. In the central nervous system, the unfolded protein response(UPR) is initiated by the activation of three transmembrane proteins: (1) PRKR-like ER kinase (PERK), (2) inositol-requiring enzyme 1α (IRE1α) and (3) activating transcription factor 6 (ATF6). Under stressed conditions, the three transmembrane proteins dissociate from glucose regulated protein 78(GRP78) and activate series of intracellular signals to alleviate the burden of endoplasmic reticulum, such as inhibiting transcription and translation to reduce the amount of proteins entering the endoplasmic reticulum, increasing the levels of molecular chaperones to enhance the folding capacity of endoplasmic reticulum.

Mild endoplasmic reticulum stress is considered to have a neuroprotective role. However, severe endoplasmic reticulum stress usually leads to apoptosis or death of neurons. IRE1α/XBP1 is the most conserved UPR signaling pathway and a key regulator of UPR. IRE1α/XBP1 signal pathway of UPR is activated in SNCA triplication iPSC neurons, resulting in culminating neurodegeneration. Conditional knockout of XBP1 in the nervous system inhibits the death of dopaminergic neurons induced by stereotaxic injections of 6-OHDA. Our previous study also demonstrates that MPP+/MPTP activates IRE1α pathway, leading to the loss of dopaminergic neurons in vitro and in vivo; Thioredoxin-1 exerts a neuroprotective effect via inhibiting the activation of IRE1α. Overexpression of human α-synuclein activates endoplasmic reticulum stress via activation of PERK and ATF6 signaling pathways as well as the upregulation of proaoptotic CHOP in dopaminergic neurons in SNc, which is inhibited by overexpression of glucose regulated protein 78. Rifampicin protects PC12 cells against the cytotoxicity of PD neurotoxin rotenone by upregulating GRP78 expression via PERK/eIF2α/ATF4 pathway. Endoplasmic reticulum stress signaling is enhanced in PINK1 and Parkin mutants model of PD, and genetic or pharmacological inhibition of PERK is protective. The N370S mutation of GBA1 gene produces a significant reduction in GCase 1 protein and enzyme activity, and retention within the endoplasmic reticulum, which interrupted its traffic to the lysosome and further led to endoplasmic reticulum stress activation and triggered UPR and Golgi apparatus fragmentation. Sustained activation of ATF4 does not repress human alpha-synuclein overexpression-induced neurodegeneration and induces severe apoptosis of dopaminergic neurons in a rat model of PD. Recently, have presented a new model of PD, intranigral injection of Tunicamycin, in which the endoplasmic reticulum stressor recapitulates some of the phenotypic characteristics observed in rodent models of PD (such as locomotor impairment, α-synuclein oligomerization, and loss of dopaminergic neurons), reinforcing that endoplasmic reticulum stress could be an important contributor to the development of PD.

Impaired Autophagy

Autophagy plays a critical role in the clearance of accumulated misfolded proteins and degradation of damaged organelles. Resembling endoplasmic reticulum stress, the initial autophagy is also widely considered to be cyto-protective. Overexpression of autophagy-related gene 5 inhibits the apoptosis of dopaminergic neurons in MPTP-induced zebrafish model of PD. It can be achieved to inhibit the accumulation of α-synuclein by activating mTOR-dependent macroautophagy. DJ-1 reduced the accumulation and aggregation of α-synuclein via chaperone-mediated autophagy in both SH-SY5Y cells and PD animal models. Interaction between PINK-1 and α-synuclein in the cytoplasm, which is dependent on the kinase activity of PINK1 and is abolished by point mutation of G309D in its kinase domain, enhanced the degradation of toxic α-synuclein via activation of autophagy. Endoplasmic reticulum stressors, including thapsigargin, tunicamycin, 2-mercaptoethanol and Brefeldin A, activate PERK and then recruit MKK4 to lysosomes, accompanied by the activation of p38 MAPK which directly phosphorylates the receptor LAMP2A at sites T211 and T213, and further triggers chaperone-mediated autophagy to provide a pro-survival mechanism.

However, autophagy is usually defective or inhibited in the pathology of PD. Impairment of autophagy has been implicated as a causative mechanism in the development of PD. The autophagy levels in dopaminergic brain areas of α-synuclein mutant A53T transgenic mice are reduced when compared to wide-type mice. Inhibition of autophagy boosts α-synuclein release and transfer from cell to cell via extracellular vesicles, and consequent progression of synucleinopathies. have demonstrated that pathogenic α-synuclein mutations, such as A53T and A30P, could bind to the receptors on the lysosomal membrane and inhibit chaperone-mediated autophagy, resulting in accumulation of abnormal α-synuclein in the Lewy bodies and subsequent parkinsonism. Inhibition of chaperone-mediated autophagy results in progressive loss of dopaminergic neurons in SNc, severe decrease of dopamine levels in striatum, and motor deficits. The mitochondria of neurons, suffering from oxidative stress and dysfunction, can’t be removed by impaired mitophagy in PD, leading to the accumulation of dysfunctional mitochondria. The formation of S-Nitrosylated PINK1 reduces the translocation of Parkin to mitochondrial membranes and inhibits mitophagy in human iPSC-derived cells as well as in α-synuclein transgenic PD mice, which contributes to neuronal cell death. GBA1 mutation produces an accumulation of cholesterol, which alters autophagy-lysosome function and impairs autophagy, rendering the neurons more vulnerable and sensitive to apoptosis. Elevated RTP801, product of DNA damage inducible transcript 4, represses autophagy, then increases the accumulation of oligomeric α-synuclein and further aggravates ER stress-induced neuronal apoptosis.

Deregulation of Immunity

Increasing evidence indicates that the immune system plays a role in the development of PD. Several previous studies have demonstrated that pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-6 and IFN-γ, are upregulated in both cerebrospinal fluid and post-mortem brain of PD patients. Massive studies have demonstrated that microglia are activated in neurotoxins-induced PD models, including MPTP, 6-OHDA and rotenone.

There is an intimate relation between α-synuclein and immune system. In a rat α-synuclein overexpressing model of PD, microglia are also activated in the striatum, accompanying the upregulation of TNF-α, IL-1β, and IFN-γ. Lack of IFN-β function shows an increase of α-synuclein-containing Lewy bodies, a reduction of dopaminergic neurons and impairment of dopamine signaling in SNc. In contrast, overexpression of IFN-β inhibits the loss of dopaminergic neuron in a model of familial PD. A recent study has showed that T cells from PD patients recognize α-synuclein peptides as antigenic epitopes which may explain the association of PD with specific major histocompatibility complex alleles. Major histocompatibility complex I is expressed in human SNc neurons and is inducible in human stem cell-derived dopaminergic neurons. Dopaminergic neurons internalize foreign ovalbumin and display antigen derived from this protein by major histocompatibility complex I to activate T cells, resulting in autoimmune responses and dopaminergic neurons death. α-synuclein induces the entry of pro-inflammatory peripheral CCR2+ monocytes into SNc, promotes the expression of major histocompatibility complex II and the subsequent degeneration of dopaminergic neurons. Genetic allelic variants of Mhc2ta, the major regulator of major histocompatibility complex II expression, regulates α-synuclein-induced microglial activation and the neurodegeneration of dopaminergic neurons.

Other PD-linked gene mutations also exhibit an association with immune system. Immune system and endocytosis are involved in the pathology of sporadic PD forms and LRRK2 G2019S carrying patients. LRRK2 G2019S could alter the differentiation of bone marrow myelopoiesis and immune homeostasis. PINK1 deficiency serves as an early modulator of innate immunity in neurons, because PINK1/Parkin could suppress inflammatory conditions triggered immune-response-eliciting pathway by inhibiting mitochondrial antigen presentation. At last, we may draw a conclusion that PD is an autoimmune disorder and deregulation of immunity is responsible for parkinsonism.

Conclusion and Expectation

In summary, pathology of PD is compositive and due to the combined action of heredity and environmental factors. Mutations of single-gene or multi-genes could aggravate the effects of environmental neurotoxins. The pathogenesis of mutations linked to PD are associated with dysfunctions of mitochondria and endoplasmic reticulum, impairment of autophagy, and deregulation of immunity. Conversely, environmental neurotoxins could also deregulate the expression of PD-linked genes.

Although PD is widely researched and the therapy is positively explored, it is still incurable and persecutes tens of million sufferers worldwide. Many scientists are unremittingly searching for potential treating approaches. have demonstrated that lymphocyte-activation gene 3 interact with misfolded preformed fibrils of α-synuclein, initiates its neuron-to-neuron transmission and then induces loss of dopaminergic neurons. Using an unbiased screen targeting endogenous gene expression, have discovered that the β2-adrenoreceptor (β2AR) is a regulator of the α-synuclein gene. Salbutamol, a β2AR agonist, reduced the risk of developing PD. On the other hand, a β2AR antagonist correlated with increased risk. What’s more, activation of β2AR protected PD patient-derived cells and model mice. Gut bacteria are required for motor deficits, microglia activation, and α-synuclein pathology, suggesting that alterations in the human microbiome may increase the risk for PD. Targeting these aspects may provide effective and safe treatments to halt or slow the progression of PD.

have developed a DART (drugs acutely restricted by tethering), which antagonizes the a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor (AMPAR, a postsynaptic glutamate receptor), and applied the technique to a mouse model of PD. Human induced pluripotent stem cells-derived dopaminergic progenitor cells could function as midbrain dopaminergic neurons after transplantation in a monkey model of PD. Using three transcription factors (NEUROD1, LMX1A, and ASCL1), miR218 and collectively designated NeAL218, dopamine neurons are generated by directly reprogramming human astrocytes in vitro and mouse astrocytes in vivo. Ambroxol, which was initially used to treat airway mucus hypersecretion and hyaline membrane disease in infants and was then recognized as a pH-dependent, mixed-type inhibitor of GCase1, acts as a chaperone for GCase1 and enhances lysosomal function and autophagy. Clinical trials of ambroxol are currently ongoing in PD and PD dementia. These studies might also provide new and alternative strategies to treat PD.

Author Contributions

X-SZ and J-JJ designed the article contents and wrote the original paper. X-SZ, W-SG, J-JJ, LC, and P-PZ searched the related literature and discussed the writing. X-SZ, W-SG, and J-JJ revised the paper.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 203

  1. 1.
    Neuroprotective Effects of a Standardized Flavonoid Extract from Safflower against a Rotenone-Induced Rat Model of Parkinson’s Disease · 2016
    Not checked
  2. 2.

    Akiyama H. McGeer P. L. (1989 ). Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res. 489 247–253.

    Not in our library10.1016/0006-8993(89)90857-3

  3. 3.

    Alarcon-Aris D. Recasens A. Galofre M. Carballo-Carbajal I. Zacchi N. Ruiz-Bronchal E. (2017 ). Selective alpha-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for Parkinson’s disease. Mol. Ther. 26 550–567.

    Not in our library10.1016/j.ymthe.2017.11.015

  4. 4.

    Ando M. Fiesel F. C. Hudec R. Caulfield T. R. Ogaki K. Gorka-Skoczylas P. (2017 ). The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Mol. Neurodegener. 12:32.

    Not in our library10.1186/s13024-017-0174-z

  5. 5.

    Bae E. J. Yang N. Y. Lee C. Lee H. J. Kim S. Sardi S. P. (2015 ). Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and alpha-synuclein aggregation. Exp. Mol. Med. 47:e153.

    Not in our library10.1038/emm.2014.128

  6. 6.

    Bai J. Nakamura H. Kwon Y. W. Tanito M. Ueda S. Tanaka T. (2007 ). Does thioredoxin-1 prevent mitochondria- and endoplasmic reticulum-mediated neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine? Antioxid. Redox Signal. 9 603–608.

    Not in our library10.1089/ars.2006.1513

  7. 7.

    Balestrino R. Schapira A. H. V. (2018 ). Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications. Neuroscientist [Epub ahead of print].

    Not in our library10.1177/1073858417748875

  8. 8.

    Bandres-Ciga S. Cookson M. R. (2017 ). Alpha-synuclein triggers T-cell response. Is Parkinson’s disease an autoimmune disorder?. Mov. Disord. 32:1327.

    Not in our library10.1002/mds.27116

  9. 9.

    Batelli S. Invernizzi R. W. Negro A. Calcagno E. Rodilossi S. Forloni G. (2015 ). The Parkinson’s disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity. Neurodegener. Dis. 15 13–23.

    Not in our library10.1159/000367993

  10. 10.

    Bekris L. M. Mata I. F. Zabetian C. P. (2010 ). The genetics of Parkinson disease. J. Geriatr. Psychiatry Neurol. 23 228–242.

    Not in our library10.1177/0891988710383572

  11. 11.

    Betarbet R. Sherer T. B. MacKenzie G. Garcia-Osuna M. Panov A. V. Greenamyre J. T. (2000 ). Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci. 3 1301–1306.

    Not in our library10.1038/81834

  12. 12.
    Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson’s disease · 2017
    No notice
  13. 13.

    Biosa A. Sandrelli F. Beltramini M. Greggio E. Bubacco L. Bisaglia M. (2017 ). Recent findings on the physiological function of DJ-1: beyond Parkinson’s disease. Neurobiol. Dis. 108 65–72.

    Not in our library10.1016/j.nbd.2017.08.005

  14. 14.

    Blum-Degen D. Muller T. Kuhn W. Gerlach M. Przuntek H. Riederer P. (1995 ). Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci. Lett. 202 17–20.

    Not in our library10.1016/0304-3940(95)12192-7

  15. 15.

    Bonifacino J. S. Hurley J. H. (2008 ). Retromer. Curr. Opin. Cell Biol. 20 427–436.

    Not in our library10.1016/j.ceb.2008.03.009

  16. 16.

    Bonifati V. Rizzu P. Squitieri F. Krieger E. Vanacore N. van Swieten J. C. (2003 ). DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol. Sci. 24 159–160.

    Not in our library10.1007/s10072-003-0108-0

  17. 17.

    Brito-Armas J. M. Baekelandt V. Castro-Hernandez J. R. Gonzalez-Hernandez T. Rodriguez M. Castro R. (2013 ). Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein. Histol. Histopathol. 28 999–1006.

    Not in our library10.14670/hh-28.999

  18. 18.

    Brodacki B. Staszewski J. Toczylowska B. Kozlowska E. Drela N. Chalimoniuk M. (2008 ). Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci. Lett. 441 158–162.

    Not in our library10.1016/j.neulet.2008.06.040

  19. 19.

    Burbulla L. F. Song P. Mazzulli J. R. Zampese E. Wong Y. C. Jeon S. (2017 ). Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science 357 1255–1261.

    Not in our library10.1126/science.aam9080

  20. 20.

    Cai Y. Arikkath J. Yang L. Guo M. L. Periyasamy P. Buch S. (2016 ). Interplay of endoplasmic reticulum stress and autophagy in neurodegenerative disorders. Autophagy 12 225–244.

    Not in our library10.1080/15548627.2015.1121360

  21. 21.

    Cannon J. R. Geghman K. D. Tapias V. Sew T. Dail M. K. Li C. (2013 ). Expression of human E46K-mutated alpha-synuclein in BAC-transgenic rats replicates early-stage Parkinson’s disease features and enhances vulnerability to mitochondrial impairment. Exp. Neurol. 240 44–56.

    Not in our library10.1016/j.expneurol.2012.11.007

  22. 22.

    Cebrian C. Zucca F. A. Mauri P. Steinbeck J. A. Studer L. Scherzer C. R. (2014 ). MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat. Commun. 5:3633.

    Not in our library10.1038/ncomms4633

  23. 23.
    Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson’s disease · 2016
    No notice
  24. 24.

    Chen Y. F. Chang Y. Y. Lan M. Y. Chen P. L. Lin C. H. (2017 ). Identification of VPS35 p.D620N mutation-related Parkinson’s disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review. BMC Neurol. 17:191.

    Not in our library10.1186/s12883-017-0972-5

  25. 25.

    Choi W. S. Palmiter R. D. Xia Z. (2011 ). Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson’s disease model. J. Cell Biol. 192 873–882.

    Not in our library10.1083/jcb.201009132

  26. 26.

    Chung C. Y. Koprich J. B. Siddiqi H. Isacson O. (2009 ). Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 29 3365–3373.

    Not in our library10.1523/jneurosci.5427-08.2009

  27. 27.
    Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage · 2013
    No notice
  28. 28.

    Colla E. Coune P. Liu Y. Pletnikova O. Troncoso J. C. Iwatsubo T. (2012 ). Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. J. Neurosci. 32 3306–3320.

    Not in our library10.1523/jneurosci.5367-11.2012

  29. 29.

    Connolly N. M. C. Theurey P. Adam-Vizi V. Bazan N. G. Bernardi P. Bolanos J. P. (2017 ). Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases. Cell Death Differ. 25 542–572.

    Not in our library10.1038/s41418-017-0020-4

  30. 30.
    Activation of the mitochondrial unfolded protein response promotes longevity and dopamine neuron survival in Parkinson’s disease models · 2017
    No notice
  31. 31.
    Systemic exosomal siRNA delivery reduced alpha‐synuclein aggregates in brains of transgenic mice · 2014
    No notice
  32. 32.

    Coppola-Segovia V. Cavarsan C. Maia F. G. Ferraz A. C. Nakao L. S. Lima M. M. (2017 ). ER stress induced by tunicamycin triggers alpha-synuclein oligomerization, dopaminergic neurons death and locomotor impairment: a new model of Parkinson’s disease. Mol. Neurobiol. 54 5798–5806.

    Not in our library10.1007/s12035-016-0114-x

  33. 33.

    Cuervo A. M. Stefanis L. Fredenburg R. Lansbury P. T. Sulzer D. (2004 ). Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305 1292–1295.

    Not in our library10.1126/science.1101738

  34. 34.

    Dabbeni-Sala F. Di Santo S. Franceschini D. Skaper S. D. Giusti P. (2001 ). Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J. 15 164–170.

    Not in our library10.1096/fj.00-0129com

  35. 35.

    Deeg S. Gralle M. Sroka K. Bahr M. Wouters F. S. Kermer P. (2010 ). BAG1 restores formation of functional DJ-1 L166P dimers and DJ-1 chaperone activity. J. Cell Biol. 188 505–513.

    Not in our library10.1083/jcb.200904103

  36. 36.

    Dirkx M. F. den Ouden H. E. Aarts E. Timmer M. H. Bloem B. R. Toni I. (2017 ). Dopamine controls Parkinson’s tremor by inhibiting the cerebellar thalamus. Brain 140 721–734.

    Not in our library10.1093/brain/aww331

  37. 37.
    Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson’s Disease-like Dementia · 2015
    No notice
  38. 38.

    Fang F. Yang W. Florio J. B. Rockenstein E. Spencer B. Orain X. M. (2017 ). Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson’s disease. Sci. Rep. 7:3868.

    Not in our library10.1038/s41598-017-04232-4

  39. 39.

    Farrer M. Kachergus J. Forno L. Lincoln S. Wang D. S. Hulihan M. (2004 ). Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55 174–179.

    Not in our library10.1002/ana.10846

  40. 40.

    Feng C. W. Hung H. C. Huang S. Y. Chen C. H. Chen Y. R. Chen C. Y. (2016 ). Neuroprotective effect of the marine-derived compound 11-Dehydrosinulariolide through DJ-1-related pathway in in vitro and in vivo models of Parkinson’s disease. Mar. Drugs 14:E187.

    Not in our library10.3390/md14100187

  41. 41.

    Ferreira M. Massano J. (2017 ). An updated review of Parkinson’s disease genetics and clinicopathological correlations. Acta Neurol. Scand. 135 273–284.

    Not in our library10.1111/ane.12616

  42. 42.

    Follett J. Bugarcic A. Yang Z. Ariotti N. Norwood S. J. Collins B. M. (2016 ). Parkinson disease-linked Vps35 R524W mutation impairs the endosomal association of retromer and induces α-synuclein aggregation. J. Biol. Chem. 291 18283–18298.

    Not in our library10.1074/jbc.m115.703157

  43. 43.

    Fouillet A. Levet C. Virgone A. Robin M. Dourlen P. Rieusset J. (2012 ). ER stress inhibits neuronal death by promoting autophagy. Autophagy 8 915–926.

    Not in our library10.4161/auto.19716

  44. 44.

    Gandhi S. Vaarmann A. Yao Z. Duchen M. R. Wood N. W. Abramov A. Y. (2012 ). Dopamine induced neurodegeneration in a PINK1 model of Parkinson’s disease. PLoS One 7:e37564.

    Not in our library10.1371/journal.pone.0037564

  45. 45.

    Gan-Or Z. Dion P. A. Rouleau G. A. (2015 ). Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. Autophagy 11 1443–1457.

    Not in our library10.1080/15548627.2015.1067364

  46. 46.

    Gao F. Yang J. Wang D. Li C. Fu Y. Wang H. (2017 ). Mitophagy in Parkinson’s disease: pathogenic and therapeutic implications. Front. Neurol. 8:527

    Not in our library10.3389/fneur.2017.00527

  47. 47.

    Garcia-Sanz P. Orgaz L. Bueno-Gil G. Espadas I. Rodriguez-Traver E. Kulisevsky J. (2017 ). N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson’s disease. Mov. Disord. 32 1409–1422.

    Not in our library10.1002/mds.27119

  48. 48.

    Garcia-Sanz P. Orgaz L. Fuentes J. M. Vicario C. Moratalla R. (2018 ). Cholesterol and multilamellar bodies: lyosomal dysfunction in GBA-Parkinson disease. Autophagy 25 1–7.

    Not in our library10.1080/15548627.2018.1427396

  49. 49.

    Giaime E. Sunyach C. Druon C. Scarzello S. Robert G. Grosso S. (2010 ). Loss of function of DJ-1 triggered by Parkinson’s disease-associated mutation is due to proteolytic resistance to caspase-6. Cell Death Differ. 17 158–169.

    Not in our library10.1038/cdd.2009.116

  50. 50.

    Goldstein D. S. Kopin I. J. Sharabi Y. (2014 ). Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol. Ther. 144 268–282.

    Not in our library10.1016/j.pharmthera.2014.06.006

  51. 51.

    Goldstein D. S. Sullivan P. Cooney A. Jinsmaa Y. Sullivan R. Gross D. J. (2012 ). Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson’s disease. J. Neurochem. 123 932–943.

    Not in our library10.1111/j.1471-4159.2012.07924.x

  52. 52.

    Gorbatyuk M. S. Shabashvili A. Chen W. Meyers C. Sullivan L. F. Salganik M. (2012 ). Glucose regulated protein 78 diminishes alpha-synuclein neurotoxicity in a rat model of Parkinson disease. Mol. Ther. 20 1327–1337.

    Not in our library10.1038/mt.2012.28

  53. 53.
    Mitochondrial DNA Depletion in Respiratory Chain–Deficient P arkinson Disease Neurons · 2016
    No notice
  54. 54.

    Gully J. C. Sergeyev V. G. Bhootada Y. Mendez-Gomez H. Meyers C. A. Zolotukhin S. (2016 ). Up-regulation of activating transcription factor 4 induces severe loss of dopamine nigral neurons in a rat model of Parkinson’s disease. Neurosci. Lett. 627 36–41.

    Not in our library10.1016/j.neulet.2016.05.039

  55. 55.

    Han K. A. Shin W. H. Jung S. Seol W. Seo H. Ko C. (2017 ). Leucine-rich repeat kinase 2 exacerbates neuronal cytotoxicity through phosphorylation of histone deacetylase 3 and histone deacetylation. Hum. Mol. Genet. 26 1–18.

    Not in our library10.1093/hmg/ddw363

  56. 56.

    Haque M. E. Mount M. P. Safarpour F. Abdel-Messih E. Callaghan S. Mazerolle C. (2012 ). Inactivation of Pink1 gene in vivo sensitizes dopamine-producing neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and can be rescued by autosomal recessive Parkinson disease genes, Parkin or DJ-1. J. Biol. Chem. 287 23162–23170.

    Not in our library10.1074/jbc.m112.346437

  57. 57.

    Harms A. S. Thome A. D. Yan Z. Schonhoff A. M. Williams G. P. Li X. (2018 ). Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. Exp. Neurol. 300 179–187.

    Not in our library10.1016/j.expneurol.2017.11.010

  58. 58.
    Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study · 2008
    No notice
  59. 59.

    Heman-Ackah S. M. Manzano R. Hoozemans J. J. M. Scheper W. Flynn R. Haerty W. (2017 ). Alpha-synuclein induces the unfolded protein response in Parkinson’s disease SNCA triplication iPSC-derived neurons. Hum. Mol. Genet. 26 4441–4450.

    Not in our library10.1093/hmg/ddx331

  60. 60.

    Herrera A. Munoz P. Steinbusch H. W. M. Segura-Aguilar J. (2017 ). Are dopamine oxidation metabolites involved in the loss of dopaminergic neurons in the nigrostriatal system in Parkinson’s disease? ACS Chem. Neurosci. 8 702–711.

    Not in our library10.1021/acschemneuro.7b00034

  61. 61.

    Ho D. H. Jang J. Joe E. H. Son I. Seo H. Seol W. (2016 ). G2385R and I2020T mutations increase LRRK2 GTPase activity. Biomed. Res. Int. 2016:7917128.

    Not in our library10.1155/2016/7917128

  62. 62.

    Howlett E. H. Jensen N. Belmonte F. Zafar F. Hu X. Kluss J. (2017 ). LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease. Hum. Mol. Genet. 26 4340–4351.

    Not in our library10.1093/hmg/ddx320

  63. 63.

    Hu Z. Y. Chen B. Zhang J. P. Ma Y. Y. (2017 ). Up-regulation of autophagy-related gene 5 (ATG5) protects dopaminergic neurons in a zebrafish model of Parkinson’s disease. J. Biol. Chem. 292 18062–18074.

    Not in our library10.1074/jbc.m116.764795

  64. 64.

    Huang E. Qu D. Huang T. Rizzi N. Boonying W. Krolak D. (2017 ). PINK1-mediated phosphorylation of LETM1 regulates mitochondrial calcium transport and protects neurons against mitochondrial stress. Nat. Commun. 8:1399.

    Not in our library10.1038/s41467-017-01435-1

  65. 65.

    Ibanez L. Dube U. Saef B. Budde J. Black K. Medvedeva A. (2017 ). Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. BMC Neurol. 17:198.

    Not in our library10.1186/s12883-017-0978-z

  66. 66.

    Im J. Y. Lee K. W. Woo J. M. Junn E. Mouradian M. M. (2012 ). DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. Hum. Mol. Genet. 21 3013–3024.

    Not in our library10.1093/hmg/dds131

  67. 67.

    Ishikawa S. Taira T. Niki T. Takahashi-Niki K. Maita C. Maita H. (2009 ). Oxidative status of DJ-1-dependent activation of dopamine synthesis through interaction of tyrosine hydroxylase and 4-dihydroxy-L-phenylalanine (L-DOPA) decarboxylase with DJ-1. J. Biol. Chem. 284 28832–28844.

    Not in our library10.1074/jbc.m109.019950

  68. 68.

    Jiang M. Porat-Shliom Y. Pei Z. Cheng Y. Xiang L. Sommers K. (2010 ). Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism. J. Neurochem. 114 419–429.

    Not in our library10.1111/j.1471-4159.2010.06752.x

  69. 69.

    Jimenez-Ferrer I. Jewett M. Tontanahal A. Romero-Ramos M. Swanberg M. (2017 ). Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to alpha-synuclein-induced dopaminergic neurodegeneration. Neurobiol. Dis. 106 279–290.

    Not in our library10.1016/j.nbd.2017.07.016

  70. 70.

    Jing X. Shi Q. Bi W. Zeng Z. Liang Y. Wu X. (2014 ). Rifampicin protects PC12 cells from rotenone-induced cytotoxicity by activating GRP78 via PERK-eIF2alpha-ATF4 pathway. PLoS One 9:e92110.

    Not in our library10.1371/journal.pone.0092110

  71. 71.

    Ju C. Gao J. Hou L. Wang L. Zhang F. Sun F. (2017 ). Neuroprotective effect of chondroitin sulfate on SHSY5Y cells overexpressing wild-type or A53T mutant alphasynuclein. Mol. Med. Rep. 16 8721–8728.

    Not in our library10.3892/mmr.2017.7725

  72. 72.

    Kang S. S. Zhang Z. Liu X. Manfredsson F. P. Benskey M. J. Cao X. (2017 ). TrkB neurotrophic activities are blocked by alpha-synuclein, triggering dopaminergic cell death in Parkinson’s disease. Proc. Natl. Acad. Sci. U.S.A. 114 10773–10778.

    Not in our library10.1073/pnas.1713969114

  73. 73.
    Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice · 2017
    No notice
  74. 74.

    Karuppagounder S. S. Xiong Y. Lee Y. Lawless M. C. Kim D. Nordquist E. (2016 ). LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity. J. Chem. Neuroanat. 76 90–97.

    Not in our library10.1016/j.jchemneu.2016.01.007

  75. 75.

    Kaufman R. J. (2002 ). Orchestrating the unfolded protein response in health and disease. J. Clin. Invest. 110 1389–1398.

    Not in our library10.1172/jci0216886

  76. 76.

    Khaldy H. Escames G. Leon J. Bikjdaouene L. Acuna-Castroviejo D. (2003 ). Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. Neurobiol. Aging 24 491–500.

    Not in our library10.1016/s0197-4580(02)00133-1

  77. 77.

    Kikuchi T. Morizane A. Doi D. Magotani H. Onoe H. Hayashi T. (2017 ). Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model. Nature 548 592–596.

    Not in our library10.1038/nature23664

  78. 78.

    Kilpatrick B. S. Magalhaes J. Beavan M. S. McNeill A. Gegg M. E. Cleeter M. W. (2016 ). Endoplasmic reticulum and lysosomal Ca(2)(+) stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts. Cell Calcium 59 12–20.

    Not in our library10.1016/j.ceca.2015.11.002

  79. 79.
    Impaired Inflammatory Responses in Murine Lrrk2-Knockdown Brain Microglia · 2012
    No notice
  80. 80.

    Kim S. Yun S. P. Lee S. Umanah G. E. Bandaru V. V. R. Yin X. (2018 ). GBA1 deficiency negatively affects physiological alpha-synuclein tetramers and related multimers. Proc. Natl. Acad. Sci. U.S.A. 115 798–803.

    Not in our library10.1073/pnas.1700465115

  81. 81.

    Klein R. L. King M. A. Hamby M. E. Meyer E. M. (2002 ). Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13 605–612.

    Not in our library10.1089/10430340252837206

  82. 82.

    Kumar A. Tamjar J. Waddell A. D. Woodroof H. I. Raimi O. G. Shaw A. M. (2017 ). Structure of PINK1 and mechanisms of Parkinson’s disease-associated mutations. Elife 6:e29985.

    Not in our library10.7554/elife.29985

  83. 83.

    Langston J. W. Ballard P. Tetrud J. W. Irwin I. (1983 ). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 979–980.

    Not in our library10.1126/science.6823561

  84. 84.

    Lee S. Oh S. T. Jeong H. J. Pak S. C. Park H. J. Kim J. (2017 ). MPTP-induced vulnerability of dopamine neurons in A53T alpha-synuclein overexpressed mice with the potential involvement of DJ-1 downregulation. Korean J. Physiol. Pharmacol. 21 625–632.

    Not in our library10.4196/kjpp.2017.21.6.625

  85. 85.
    In vivo silencing of alpha-synuclein using naked siRNA · 2008
    No notice
  86. 86.
    Phosphorylation of LAMP2A by p38 MAPK couples ER stress to chaperone-mediated autophagy · 2017
    No notice
  87. 87.

    Lieberman O. J. Choi S. J. Kanter E. Saverchenko A. Frier M. D. Fiore G. M. (2017 ). alpha-synuclein-dependent calcium entry underlies differential sensitivity of cultured SN and VTA dopaminergic neurons to a Parkinsonian neurotoxin. eNeuro 4:ENEURO.0167-17.2017.

    Not in our library10.1523/eneuro.0167-17.2017

  88. 88.

    Liu J. Wang X. Lu Y. Duan C. Gao G. Lu L. (2017 ). Pink1 interacts with alpha-synuclein and abrogates alpha-synuclein-induced neurotoxicity by activating autophagy. Cell Death Dis. 8:e3056.

    Not in our library10.1038/cddis.2017.427

  89. 89.

    Liu S. Cui B. Dai Z. X. Shi P. K. Wang Z. H. Guo Y. Y. (2016 ). Long Non-coding RNA HOTAIR promotes Parkinson’s disease induced by MPTP through up-regulating the expression of LRRK2. Curr. Neurovasc. Res. 13 115–120.

    Not in our library10.2174/1567202613666160316155228

  90. 90.

    Liu Z. Yu Y. Li X. Ross C. A. Smith W. W. (2011 ). Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacol. Res. 63 439–444.

    Not in our library10.1016/j.phrs.2011.01.004

  91. 91.

    Luth E. S. Stavrovskaya I. G. Bartels T. Kristal B. S. Selkoe D. J. (2014 ). Soluble, prefibrillar alpha-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J. Biol. Chem. 289 21490–21507.

    Not in our library10.1074/jbc.m113.545749

  92. 92.

    Lutz A. K. Exner N. Fett M. E. Schlehe J. S. Kloos K. Lammermann K. (2009 ). Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J. Biol. Chem. 284 22938–22951.

    Not in our library10.1074/jbc.m109.035774

  93. 93.
    Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease · 2016
    No notice
  94. 94.

    Mao X. Ou M. T. Karuppagounder S. S. Kam T. I. Yin X. Xiong Y. (2016 ). Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353:aah3374.

    Not in our library10.1126/science.aah3374

  95. 95.
    Sensitivity to Oxidative Stress in DJ-1-Deficient Dopamine Neurons: An ES- Derived Cell Model of Primary Parkinsonism · 2004
    No notice
  96. 96.

    Martinez B. A. Petersen D. A. Gaeta A. L. Stanley S. P. Caldwell G. A. Caldwell K. A. (2017 ). Dysregulation of the mitochondrial unfolded protein response induces non-apoptotic dopaminergic neurodegeneration in C. elegans Models of Parkinson’s Disease. J. Neurosci. 37 11085–11100.

    Not in our library10.1523/jneurosci.1294-17.2017

  97. 97.

    Mason R. J. Paskins A. R. Dalton C. F. Smith D. P. (2016 ). Copper binding and subsequent aggregation of alpha-synuclein are modulated by N-terminal acetylation and ablated by the H50Q missense mutation. Biochemistry 55 4737–4741.

    Not in our library10.1021/acs.biochem.6b00708

  98. 98.

    Matheoud D. Sugiura A. Bellemare-Pelletier A. Laplante A. Rondeau C. Chemali M. (2016 ). Parkinson’s disease-related proteins PINK1 and parkin repress mitochondrial antigen presentation. Cell 166 314–327.

    Not in our library10.1016/j.cell.2016.05.039

  99. 99.
    Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson’s disease? · 2017
    No notice
  100. 100.

    Mazzulli J. R. Zunke F. Tsunemi T. Toker N. J. Jeon S. Burbulla L. F. (2016 ). Activation of beta-glucocerebrosidase reduces pathological alpha-synuclein and restores lysosomal function in Parkinson’s patient midbrain neurons. J. Neurosci. 36 7693–7706.

    Not in our library10.1523/jneurosci.0628-16.2016

  101. 101.

    Mbefo M. K. Fares M. B. Paleologou K. Oueslati A. Yin G. Tenreiro S. (2015 ). Parkinson disease mutant E46K enhances alpha-synuclein phosphorylation in mammalian cell lines, in yeast, and in vivo. J. Biol. Chem. 290 9412–9427.

    Not in our library10.1074/jbc.m114.610774

  102. 102.

    McGeer P. L. Schwab C. Parent A. Doudet D. (2003 ). Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol. 54 599–604.

    Not in our library10.1002/ana.10728

  103. 103.

    McNeill A. Duran R. Hughes D. A. Mehta A. Schapira A. H. (2012 ). A clinical and family history study of Parkinson’s disease in heterozygous glucocerebrosidase mutation carriers. J. Neurol. Neurosurg. Psychiatry 83 853–854.

    Not in our library10.1136/jnnp-2012-302402

  104. 104.

    Meiser J. Delcambre S. Wegner A. Jager C. Ghelfi J. d’Herouel A. F. (2016 ). Loss of DJ-1 impairs antioxidant response by altered glutamine and serine metabolism. Neurobiol. Dis. 89 112–125.

    Not in our library10.1016/j.nbd.2016.01.019

  105. 105.
    Ambroxol effects in glucocerebrosidase and α‐synuclein transgenic mice · 2016
    No notice
  106. 106.

    Migdalska-Richards A. Wegrzynowicz M. Rusconi R. Deangeli G. Di Monte D. A. Spillantini M. G. (2017 ). The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice. Brain 140 2706–2721.

    Not in our library10.1093/brain/awx221

  107. 107.

    Minakaki G. Menges S. Kittel A. Emmanouilidou E. Schaeffner I. Barkovits K. (2017 ). Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. Autophagy 14 98–119.

    Not in our library10.1080/15548627.2017.1395992

  108. 108.

    Mittal S. Bjornevik K. Im D. S. Flierl A. Dong X. Locascio J. J. (2017 ). beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease. Science 357 891–898.

    Not in our library10.1126/science.aaf3934

  109. 109.

    Mogi M. Harada M. Kondo T. Riederer P. Inagaki H. Minami M. (1994a ). Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180 147–150.

    Not in our library10.1016/0304-3940(94)90508-8

  110. 110.

    Mogi M. Harada M. Riederer P. Narabayashi H. Fujita K. Nagatsu T. (1994b ). Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165 208–210.

    Not in our library10.1016/0304-3940(94)90746-3

  111. 111.

    Mor D. E. Tsika E. Mazzulli J. R. Gould N. S. Kim H. Daniels M. J. (2017 ). Dopamine induces soluble alpha-synuclein oligomers and nigrostriatal degeneration. Nat. Neurosci. 20 1560–1568.

    Not in our library10.1038/nn.4641

  112. 112.

    Mortiboys H. Aasly J. Bandmann O. (2013 ). Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson’s disease. Brain 136 3038–3050.

    Not in our library10.1093/brain/awt224

  113. 113.

    Mortiboys H. Furmston R. Bronstad G. Aasly J. Elliott C. Bandmann O. (2015 ). UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo. Neurology 85 846–852.

    Not in our library10.1212/wnl.0000000000001905

  114. 114.

    Mosharov E. V. Larsen K. E. Kanter E. Phillips K. A. Wilson K. Schmitz Y. (2009 ). Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62 218–229.

    Not in our library10.1016/j.neuron.2009.01.033

  115. 115.

    Mukherjee U. A. Ong S. B. Ong S. G. Hausenloy D. J. (2015 ). Parkinson’s disease proteins: novel mitochondrial targets for cardioprotection. Pharmacol. Ther. 156 34–43.

    Not in our library10.1016/j.pharmthera.2015.10.005

  116. 116.

    Murphy K. E. Gysbers A. M. Abbott S. K. Tayebi N. Kim W. S. Sidransky E. (2014 ). Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson’s disease. Brain 137 834–848.

    Not in our library10.1093/brain/awt367

  117. 117.

    Mutez E. Nkiliza A. Belarbi K. de Broucker A. Vanbesien-Mailliot C. Bleuse S. (2014 ). Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson’s disease. Neurobiol. Dis. 63 165–170.

    Not in our library10.1016/j.nbd.2013.11.007

  118. 118.

    Narendra D. Tanaka A. Suen D. F. Youle R. J. (2009 ). Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy 5 706–708.

    Not in our library10.4161/auto.5.5.8505

  119. 119.
    PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin · 2010
    No notice
  120. 120.

    Nguyen A. P. T. Daniel G. Valdes P. Islam M. S. Schneider B. L. Moore D. J. (2018 ). G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. Hum. Mol. Genet. 27 120–134.

    Not in our library10.1093/hmg/ddx389

  121. 121.

    Oh C. K. Sultan A. Platzer J. Dolatabadi N. Soldner F. McClatchy D. B. (2017 ). S-Nitrosylation of PINK1 attenuates PINK1/parkin-dependent mitophagy in hiPSC-based Parkinson’s disease models. Cell Rep. 21 2171–2182.

    Not in our library10.1016/j.celrep.2017.10.068

  122. 122.

    Pan P. Y. Li X. Wang J. Powell J. Wang Q. Zhang Y. (2017 ). Parkinson’s disease-associated LRRK2 hyperactive kinase mutant disrupts synaptic vesicle trafficking in ventral midbrain neurons. J. Neurosci. 37 11366–11376.

    Not in our library10.1523/jneurosci.0964-17.2017

  123. 123.

    Panneton W. M. Kumar V. B. Gan Q. Burke W. J. Galvin J. E. (2010 ). The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One 5:e15251.

    Not in our library10.1371/journal.pone.0015251

  124. 124.

    Park J. Lee J. W. Cooper S. C. Broxmeyer H. E. Cannon J. R. Kim C. H. (2017 ). Parkinson disease-associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response. J. Leukoc. Biol. 102 1093–1102.

    Not in our library10.1189/jlb.1a0417-147rr

  125. 125.

    Parnetti L. Paciotti S. Eusebi P. Dardis A. Zampieri S. Chiasserini D. (2017 ). Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson’s disease patients. Mov. Disord. 32 1423–1431.

    Not in our library10.1002/mds.27136

  126. 126.

    Polymeropoulos M. H. Lavedan C. Leroy E. Ide S. E. Dehejia A. Dutra A. (1997 ). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276 2045–2047.

    Not in our library10.1126/science.276.5321.2045

  127. 127.

    Porcari R. Proukakis C. Waudby C. A. Bolognesi B. Mangione P. P. Paton J. F. (2015 ). The H50Q mutation induces a 10-fold decrease in the solubility of alpha-synuclein. J. Biol. Chem. 290 2395–2404.

    Not in our library10.1074/jbc.m114.610527

  128. 128.

    Pupyshev A. B. Korolenko T. A. Akopyan A. A. Amstislavskaya T. G. Tikhonova M. A. (2017 ). Suppression of autophagy in the brain of transgenic mice with overexpression of capital A, Cyrillic53capital TE, Cyrillic-mutant alpha-synuclein as an early event at synucleinopathy progression. Neurosci. Lett. 672 140–142.

    Not in our library10.1016/j.neulet.2017.12.001

  129. 129.

    Puschmann A. Fiesel F. C. Caulfield T. R. Hudec R. Ando M. Truban D. (2017 ). Heterozygous PINK1 p.G411S increases risk of Parkinson’s disease via a dominant-negative mechanism. Brain 140 98–117.

    Not in our library10.1093/brain/aww261

  130. 130.

    Ramsey C. P. Giasson B. I. (2010 ). L10p and P158DEL DJ-1 mutations cause protein instability, aggregation, and dimerization impairments. J. Neurosci. Res. 88 3111–3124.

    Not in our library10.1002/jnr.22477

  131. 131.

    Rappold P. M. Cui M. Chesser A. S. Tibbett J. Grima J. C. Duan L. (2011 ). Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc. Natl. Acad. Sci. U.S.A. 108 20766–20771.

    Not in our library10.1073/pnas.1115141108

  132. 132.

    Rassu M. Del Giudice M. G. Sanna S. Taymans J. M. Morari M. Brugnoli A. (2017 ). Role of LRRK2 in the regulation of dopamine receptor trafficking. PLoS One 12:e0179082.

    Not in our library10.1371/journal.pone.0179082

  133. 133.

    Ren H. Fu K. Mu C. Zhen X. Wang G. (2012 ). L166P mutant DJ-1 promotes cell death by dissociating Bax from mitochondrial Bcl-XL. Mol. Neurodegener. 7:40.

    Not in our library10.1186/1750-1326-7-40

  134. 134.

    Rivetti di Val Cervo P. Romanov R. A. Spigolon G. Masini D. Martin-Montanez E. Toledo E. M. (2017 ). Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson’s disease model. Nat. Biotechnol. 35 444–452.

    Not in our library10.1038/nbt.3835

  135. 135.

    Rocha E. M. Smith G. A. Park E. Cao H. Brown E. Hallett P. (2015 ). Progressive decline of glucocerebrosidase in aging and Parkinson’s disease. Ann. Clin. Transl. Neurol. 2 433–438.

    Not in our library10.1002/acn3.177

  136. 136.

    Rodriguez J. A. Ivanova M. I. Sawaya M. R. Cascio D. Reyes F. E. Shi D. (2015 ). Structure of the toxic core of alpha-synuclein from invisible crystals. Nature 525 486–490.

    Not in our library10.1038/nature15368

  137. 137.

    Ross O. A. Braithwaite A. T. Skipper L. M. Kachergus J. Hulihan M. M. Middleton F. A. (2008 ). Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann. Neurol. 63 743–750.

    Not in our library10.1002/ana.21380

  138. 138.

    Rutherford N. J. Moore B. D. Golde T. E. Giasson B. I. (2014 ). Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of alpha-synuclein. J. Neurochem. 131 859–867.

    Not in our library10.1111/jnc.12806

  139. 139.

    Ryu E. J. Harding H. P. Angelastro J. M. Vitolo O. V. Ron D. Greene L. A. (2002 ). Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson’s disease. J. Neurosci. 22 10690–10698.

    Not in our library10.1523/jneurosci.22-24-10690.2002

  140. 140.

    Sampson T. R. Debelius J. W. Thron T. Janssen S. Shastri G. G. Ilhan Z. E. (2016 ). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 167 1469–1480.e12.

    Not in our library10.1016/j.cell.2016.11.018

  141. 141.

    Sanyal J. Jana A. Ghosh E. Banerjee T. K. Chakraborty D. P. Rao V. R. (2015 ). Evaluation of PARKIN gene variants in West Bengal Parkinson’s disease patients. J. Hum. Genet. 60 485–492.

    Not in our library10.1038/jhg.2015.49

  142. 142.

    Sanz F. J. Solana-Manrique C. Munoz-Soriano V. Calap-Quintana P. Molto M. D. Paricio N. (2017 ). Identification of potential therapeutic compounds for Parkinson’s disease using Drosophila and human cell models. Free Radic. Biol. Med. 108 683–691.

    Not in our library10.1016/j.freeradbiomed.2017.04.364

  143. 143.

    Sato H. Arawaka S. Hara S. Fukushima S. Koga K. Koyama S. (2011 ). Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson’s disease. J. Neurosci. 31 16884–16894.

    Not in our library10.1523/jneurosci.3967-11.2011

  144. 144.

    Schapira A. H. (2008 ). Mitochondria in the aetiology and pathogenesis of Parkinson’s disease. Lancet Neurol. 7 97–109.

    Not in our library10.1016/s1474-4422(07)70327-7

  145. 145.

    Schnabel J. (2010 ). Secrets of the shaking palsy. Nature 466 S2–S5.

    Not in our library10.1038/466s2b

  146. 146.

    Schneider S. A. Alcalay R. N. (2017 ). Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. Mov. Disord. 32 1504–1523.

    Not in our library10.1002/mds.27193

  147. 147.

    Schroder M. Kaufman R. J. (2005 ). The mammalian unfolded protein response. Annu. Rev. Biochem. 74 739–789.

    Not in our library10.1146/annurev.biochem.73.011303.074134

  148. 148.

    Selvaraj S. Sun Y. Watt J. A. Wang S. Lei S. Birnbaumer L. (2012 ). Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J. Clin. Invest. 122 1354–1367.

    Not in our library10.1172/jci61332

  149. 149.

    Sheng Y. L. Chen X. Hou X. O. Yuan X. Yuan B. S. Yuan Y. Q. (2017 ). Urate promotes SNCA/alpha-synuclein clearance via regulating mTOR-dependent macroautophagy. Exp. Neurol. 297 138–147.

    Not in our library10.1016/j.expneurol.2017.08.007

  150. 150.

    Sherer T. B. Betarbet R. Kim J. H. Greenamyre J. T. (2003 ). Selective microglial activation in the rat rotenone model of Parkinson’s disease. Neurosci. Lett. 341 87–90.

    Not in our library10.1016/s0304-3940(03)00172-1

  151. 151.

    Shields B. C. Kahuno E. Kim C. Apostolides P. F. Brown J. Lindo S. (2017 ). Deconstructing behavioral neuropharmacology with cellular specificity. Science 356:aaj2161.

    Not in our library10.1126/science.aaj2161

  152. 152.

    Sidransky E. Nalls M. A. Aasly J. O. Aharon-Peretz J. Annesi G. Barbosa E. R. (2009 ). Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N. Engl. J. Med. 361 1651–1661.

    Not in our library10.1056/nejmoa0901281

  153. 153.

    Smith W. W. Jiang H. Pei Z. Tanaka Y. Morita H. Sawa A. (2005a ). Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum. Mol. Genet. 14 3801–3811.

    Not in our library10.1093/hmg/ddi396

  154. 154.

    Smith W. W. Pei Z. Jiang H. Moore D. J. Liang Y. West A. B. (2005b ). Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 102 18676–18681.

    Not in our library10.1073/pnas.0508052102

  155. 155.

    Spillantini M. G. Schmidt M. L. Lee V. M. Trojanowski J. Q. Jakes R. Goedert M. (1997 ). Alpha-synuclein in Lewy bodies. Nature 388 839–840.

    Not in our library10.1038/42166

  156. 156.
    Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis · 2017
    No notice
  157. 157.

    Sterky F. H. Hoffman A. F. Milenkovic D. Bao B. Paganelli A. Edgar D. (2012 ). Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Hum. Mol. Genet. 21 1078–1089.

    Not in our library10.1093/hmg/ddr537

  158. 158.

    Storch A. Ludolph A. C. Schwarz J. (2004 ). Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J. Neural Transm. (Vienna). 111 1267–1286.

    Not in our library10.1007/s00702-004-0203-2

  159. 159.

    Su P. Liu F. (2017 ). A peptide disrupting the D2R-DAT interaction protects against dopamine neurotoxicity. Exp. Neurol. 295 176–183.

    Not in our library10.1016/j.expneurol.2017.05.010

  160. 160.

    Su Y. C. Guo X. Qi X. (2015 ). Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy. Biochim. Biophys. Acta 1852 12–21.

    Not in our library10.1016/j.bbadis.2014.11.009

  161. 161.

    Subramaniam S. R. Chesselet M. F. (2013 ). Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog. Neurobiol. 106–107 17–32.

    Not in our library10.1016/j.pneurobio.2013.04.004

  162. 162.

    Sulzer D. Alcalay R. N. Garretti F. Cote L. Kanter E. Agin-Liebes J. (2017 ). T cells from patients with Parkinson’s disease recognize alpha-synuclein peptides. Nature 546 656–661.

    Not in our library10.1038/nature22815

  163. 163.

    Taguchi Y. V. Liu J. Ruan J. Pacheco J. Zhang X. Abbasi J. (2017 ). Glucosylsphingosine promotes alpha-synuclein pathology in mutant GBA-associated Parkinson’s disease. J. Neurosci. 37 9617–9631.

    Not in our library10.1523/jneurosci.1525-17.2017

  164. 164.

    Taipa R. Pereira C. Reis I. Alonso I. Bastos-Lima A. Melo-Pires M. (2016 ). DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology. Brain 139 1680–1687.

    Not in our library10.1093/brain/aww080

  165. 165.

    Tang B. Xiong H. Sun P. Zhang Y. Wang D. Hu Z. (2006 ). Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson’s disease. Hum. Mol. Genet. 15 1816–1825.

    Not in our library10.1093/hmg/ddl104

  166. 166.

    Tang F. L. Erion J. R. Tian Y. Liu W. Yin D. M. Ye J. (2015a ). VPS35 in dopamine neurons is required for endosome-to-golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for α-synuclein degradation and prevention of pathogenesis of Parkinson’s disease. J. Neurosci. 35 10613–10628.

    Not in our library10.1523/jneurosci.0042-15.2015

  167. 167.

    Tang F. L. Liu W. Hu J. X. Erion J. R. Ye J. Mei L. (2015b ). VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function. Cell Rep. 12 1631–1643.

    Not in our library10.1016/j.celrep.2015.08.001

  168. 168.

    Thomas J. M. Li T. Yang W. Xue F. Fishman P. S. Smith W. W. (2016 ). 68 and FX2149 attenuate mutant LRRK2-R1441C-induced neural transport impairment. Front. Aging Neurosci. 8:337.

    Not in our library10.3389/fnagi.2016.00337

  169. 169.

    Torres-Odio S. Key J. Hoepken H. H. Canet-Pons J. Valek L. Roller B. (2017 ). Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation. J. Neuroinflammation 14:154.

    Not in our library10.1186/s12974-017-0928-0

  170. 170.

    Valdes P. Mercado G. Vidal R. L. Molina C. Parsons G. Court F. A. (2014 ). Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. Proc. Natl. Acad. Sci. U.S.A. 111 6804–6809.

    Not in our library10.1073/pnas.1321845111

  171. 171.

    Vanle B. C. Florang V. R. Murry D. J. Aguirre A. L. Doorn J. A. (2017 ). Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde. Biochem. Biophys. Res. Commun. 492 275–281.

    Not in our library10.1016/j.bbrc.2017.08.067

  172. 172.

    Verma M. Callio J. Otero P. A. Sekler I. Wills Z. P. Chu C. T. (2017 ). Mitochondrial calcium dysregulation contributes to dendrite degeneration mediated by PD/LBD-Associated LRRK2 Mutants. J. Neurosci. 37 11151–11165.

    Not in our library10.1523/jneurosci.3791-16.2017

  173. 173.
    Copper(II) and the pathological H50Q α-synuclein mutant: Environment meets genetics · 2017
    Not checked
  174. 174.

    Volpicelli-Daley L. A. Abdelmotilib H. Liu Z. Stoyka L. Daher J. P. Milnerwood A. J. (2016 ). G2019S-LRRK2 expression ments alpha-synuclein sequestration into inclusions in neurons. J. Neurosci. 36 7415–7427.

    Not in our library10.1523/jneurosci.3642-15.2016

  175. 175.

    Walter P. Ron D. (2011 ). The unfolded protein response: from stress pathway to homeostatic regulation. Science 334 1081–1086.

    Not in our library10.1126/science.1209038

  176. 176.

    Wang H. S. Toh J. Ho P. Tio M. Zhao Y. Tan E. K. (2014 ). In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila. Mol. Brain 7:73.

    Not in our library10.1186/s13041-014-0073-y

  177. 177.

    Wang K. Huang J. Xie W. Huang L. Zhong C. Chen Z. (2016 ). Beclin1 and HMGB1 ameliorate the alpha-synuclein-mediated autophagy inhibition in PC12 cells. Diagn. Pathol. 11:15.

    Not in our library10.1186/s13000-016-0459-5

  178. 178.

    Wang W. Wang X. Fujioka H. Hoppel C. Whone A. L. Caldwell M. A. (2016 ). Parkinson’s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat. Med. 22 54–63.

    Not in our library10.1038/nm.3983

  179. 179.

    Wang X. Yan M. H. Fujioka H. Liu J. Wilson-Delfosse A. Chen S. G. (2012 ). LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum. Mol. Genet. 21 1931–1944.

    Not in our library10.1093/hmg/dds003

  180. 180.

    West A. B. (2017 ). Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp. Neurol. 298 236–245.

    Not in our library10.1016/j.expneurol.2017.07.019

  181. 181.

    Winner B. Jappelli R. Maji S. K. Desplats P. A. Boyer L. Aigner S. (2011 ). In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U.S.A. 108 4194–4199.

    Not in our library10.1073/pnas.1100976108

  182. 182.

    Xiao B. Goh J. Y. Xiao L. Xian H. Lim K. L. Liou Y. C. (2017 ). Reactive oxygen species trigger Parkin/PINK1 pathway-dependent mitophagy by inducing mitochondrial recruitment of Parkin. J. Biol. Chem. 292 16697–16708.

    Not in our library10.1074/jbc.m117.787739

  183. 183.

    Xilouri M. Brekk O. R. Polissidis A. Chrysanthou-Piterou M. Kloukina I. Stefanis L. (2016 ). Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats. Autophagy 12 2230–2247.

    Not in our library10.1080/15548627.2016.1214777

  184. 184.
    DJ-1 Inhibits α-Synuclein Aggregation by Regulating Chaperone-Mediated Autophagy · 2017
    No notice
  185. 185.

    Yan J. Q. Yuan Y. H. Gao Y. N. Huang J. Y. Ma K. L. Gao Y. (2014 ). Overexpression of human E46K mutant alpha-synuclein impairs macroautophagy via inactivation of JNK1-Bcl-2 pathway. Mol. Neurobiol. 50 685–701.

    Not in our library10.1007/s12035-014-8738-1

  186. 186.

    Yan M. H. Wang X. Zhu X. (2013 ). Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic. Biol. Med. 62 90–101.

    Not in our library10.1016/j.freeradbiomed.2012.11.014

  187. 187.

    Yin F. Boveris A. Cadenas E. (2014 ). Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration. Antioxid. Redox Signal. 20 353–371.

    Not in our library10.1089/ars.2012.4774

  188. 188.

    Yoon J. H. Mo J. S. Kim M. Y. Ann E. J. Ahn J. S. Jo E. H. (2017 ). LRRK2 functions as a scaffolding kinase of ASK1-mediated neuronal cell death. Biochim. Biophys. Acta 1864 2356–2368.

    Not in our library10.1016/j.bbamcr.2017.09.001

  189. 189.

    Yun S. P. Kim H. Ham S. Kwon S. H. Lee G. H. Shin J. H. (2017 ). VPS35 regulates parkin substrate AIMP2 toxicity by facilitating lysosomal clearance of AIMP2. Cell Death Dis. 8:e2741.

    Not in our library10.1038/cddis.2017.157

  190. 190.

    Zeng X. S. Jia J. J. Kwon Y. Wang S. D. Bai J. (2014 ). The role of thioredoxin-1 in suppression of endoplasmic reticulum stress in Parkinson disease. Free Radic. Biol. Med. 67 10–18.

    Not in our library10.1016/j.freeradbiomed.2013.10.013

  191. 191.

    Zhang S. Eitan E. Wu T. Y. Mattson M. P. (2018 ). Intercellular transfer of pathogenic alpha-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal. Neurobiol. Aging 61 52–65.

    Not in our library10.1016/j.neurobiolaging.2017.09.016

  192. 192.

    Zhang W. Dallas S. Zhang D. Guo J. P. Pang H. Wilson B. (2007 ). Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 55 1178–1188.

    Not in our library10.1002/glia.20532

  193. 193.

    Zhang Y. Gong X. G. Wang Z. Z. Sun H. M. Guo Z. Y. Hu J. H. (2016 ). Overexpression of DJ-1/PARK7, the Parkinson’s disease-related protein, improves mitochondrial function via Akt phosphorylation on threonine 308 in dopaminergic neuron-like cells. Eur. J. Neurosci. 43 1379–1388.

    Not in our library10.1111/ejn.13216

  194. 194.

    Zhang Z. Chu S. F. Wang S. S. Jiang Y. N. Gao Y. Yang P. F. (2017 ). RTP801 is a critical factor in the neurodegeneration process of A53T alpha-synuclein in a mouse model of Parkinson’s disease under chronic restraint stress. Br. J. Pharmacol. 175 590–605.

    Not in our library10.1111/bph.14091

  195. 195.

    Zhao H. T. John N. Delic V. Ikeda-Lee K. Kim A. Weihofen A. (2017 ). LRRK2 antisense oligonucleotides ameliorate alpha-synuclein inclusion formation in a Parkinson’s disease mouse model. Mol. Ther. Nucleic Acids 8 508–519.

    Not in our library10.1016/j.omtn.2017.08.002

  196. 196.

    Zharikov A. D. Cannon J. R. Tapias V. Bai Q. Horowitz M. P. Shah V. (2015 ). shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson’s disease model. J. Clin. Invest. 125 2721–2735.

    Not in our library10.1172/jci64502

  197. 197.

    Zhou L. Wang W. Hoppel C. Liu J. Zhu X. (2017 ). Parkinson’s disease-associated pathogenic VPS35 mutation causes complex I deficits. Biochim. Biophys. Acta 1863 2791–2795.

    Not in our library10.1016/j.bbadis.2017.07.032

  198. 198.

    Zhou Z. D. Kerk S. Y. Xiong G. G. Lim T. M. (2009 ). Dopamine auto-oxidation aggravates non-apoptotic cell death induced by over-expression of human A53T mutant alpha-synuclein in dopaminergic PC12 cells. J. Neurochem. 108 601–610.

    Not in our library10.1111/j.1471-4159.2008.05795.x

  199. 199.

    Zhu M. S. H Patel S. Han S. (2017 ). DJ-1, a Parkinson’s disease related protein, aggregates under denaturing conditions and co-aggregates with alpha-synuclein through hydrophobic interaction. Biochim. Biophys. Acta 1861 1759–1769.

    Not in our library10.1016/j.bbagen.2017.03.013

  200. 200.

    Zhuang N. Li L. Chen S. Wang T. (2016 ). PINK1-dependent phosphorylation of PINK1 and Parkin is essential for mitochondrial quality control. Cell Death Dis. 7:e2501.

    Not in our library10.1038/cddis.2016.396

  201. 201.

    Zimprich A. Biskup S. Leitner P. Lichtner P. Farrer M. Lincoln S. (2004 ). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 601–607.

    Not in our library10.1016/j.neuron.2004.11.005

  202. 202.

    Zondler L. Kostka M. Garidel P. Heinzelmann U. Hengerer B. Mayer B. (2017 ). Proteasome impairment by alpha-synuclein. PLoS One 12:e0184040.

    Not in our library10.1371/journal.pone.0184040

  203. 203.
    DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson’s disease · 2014
    No notice

Cited by papers we hold 10

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.